Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Vote In favor of Your Favored Kind Of Vegetable - 2Mystery foot suggests a second early human relative lived alongside Lucy
- 3Mossad unveils network of Hamas terror infrastructure across Europe
- 4The Golden Globes is happening Sunday: Who's nominated, who's hosting and how to watch
- 5Share your number one city visit transport that leaves a mark on the world wake up!
- Watch India launch advanced military satellite on rocket's 1st flight since May 2025 failure
- German finance minister seeks better market access in China talks
- Electric Vehicles for Eco-Accommodating Driving
- NASA loses contact with its Maven spacecraft orbiting Mars for the past decade
- Hundreds show fascist salute at rally in Rome in annual ritual
- This Huge Ocean Beast Shifts Sharks’ Evolutionary Timeline
- Motivational Travel Objections for History Buffs
- Holiday destinations for Creature Sweethearts
- Vote in favor of the handheld vacuum that you love for its strong attractions!
